S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:EVLO

Evelo Biosciences (EVLO) Stock Forecast, Price & News

$0.15
+0.02 (+17.27%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$0.13
$0.15
50-Day Range
$0.10
$0.25
52-Week Range
$0.02
$3.29
Volume
1.11 million shs
Average Volume
2.41 million shs
Market Capitalization
$16.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.17

Evelo Biosciences MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
1,991.6% Upside
$3.17 Price Target
Short Interest
Healthy
3.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of Evelo Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$14,144 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.74) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

833rd out of 1,010 stocks

Pharmaceutical Preparations Industry

415th out of 494 stocks


EVLO stock logo

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Evelo Biosciences (EVLO) Gets a Hold from Morgan Stanley
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
Evelo Biosciences Provides Clinical Updates
EVLO Evelo Biosciences, Inc.
Earnings Preview: Evelo Biosciences
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings
3/16/2023
Today
5/28/2023
Next Earnings (Estimated)
6/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.17
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,991.6%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-114,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.24) per share

Miscellaneous

Free Float
102,810,000
Market Cap
$16.96 million
Optionable
Not Optionable
Beta
1.26

Key Executives

  • Simba Gill
    President, Chief Executive Officer & Director
  • Ann Marella Thorell
    CFO, Treasurer, SVP & Chief Accounting Officer
  • Mark W. Bodmer
    Chief Scientific Officer, President-R&D
  • Chun Zhang
    Chief Technical Operations & Quality Officer
  • Andrea Itano
    Senior Vice President & Head-Research













EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings
or view top-rated stocks.

What is Evelo Biosciences' stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price objectives for Evelo Biosciences' shares. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.17 in the next year. This suggests a possible upside of 1,991.6% from the stock's current price.
View analysts price targets for EVLO
or view top-rated stocks among Wall Street analysts.

How have EVLO shares performed in 2023?

Evelo Biosciences' stock was trading at $1.61 on January 1st, 2023. Since then, EVLO shares have decreased by 90.6% and is now trading at $0.1514.
View the best growth stocks for 2023 here
.

Are investors shorting Evelo Biosciences?

Evelo Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,570,000 shares, an increase of 58.7% from the April 30th total of 2,250,000 shares. Based on an average daily trading volume, of 3,620,000 shares, the short-interest ratio is presently 1.0 days.
View Evelo Biosciences' Short Interest
.

When is Evelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 1st 2023.
View our EVLO earnings forecast
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.60%), BlackRock Inc. (1.04%), CVI Holdings LLC (0.76%), Susquehanna International Group LLP (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David R Epstein, Duncan Mchale, Marella Thorell, Simba Gill, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends
.

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $0.15.

How much money does Evelo Biosciences make?

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $16.96 million. The company earns $-114,530,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

How many employees does Evelo Biosciences have?

The company employs 122 workers across the globe.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -